Preliminary results of the Cardiac Arrest Study Hamburg (CASH)

Jürgen Siebels, Riccardo Cappato, Rudolf Rüppel, Michael A E Schneider, Karl H. Kuck, CASH Investigators The CASH Investigators

Research output: Contribution to journalArticlepeer-review


Sodium channel Mockers and class III antiarrhythmic compounds, as well as β blockers, have been used in preventing recurrences of sudden cardiac death. In recent years, implantable cardioverter-defibrillators (ICDs) have been used increasingly, but no data from randomized trials comparing antiarrhythmic drug and ICD therapy have been reported in this setting. In 1987, the Cardiac Arrest Study Hamburg (CASH), a prospective, randomized trial, was initiated to compare metoprolol, amiodarone, propafenone, and ICD implantation in patients surviving sudden cardiac death due to documented ventricular tachycardia and/or ventricular fibrillation. The details of the study design and preliminary results are presented herein. The primary endpoint of the study is total mortality. The data reviewed in March 1992, representing a mean follow-up period of 11 months, indicated no significant differences among patients randomized to metoprolol, amiodarone, and ICDs. However, there was a significantly higher total mortality and cardiac arrest recurrence in patients randomized to propafenone compared with those randomized to the ICD treatment limb. The study continues with the deletion of the propafenone treatment limb.

Original languageEnglish
JournalThe American Journal of Cardiology
Issue number16
Publication statusPublished - Nov 26 1993

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Preliminary results of the Cardiac Arrest Study Hamburg (CASH)'. Together they form a unique fingerprint.

Cite this